Products for Research Use Only

Cabazitaxel-d9

CAT: 0804-HY-15459S1Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15459S1Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cabazitaxel-d9 is deuterium labeled Cabazitaxel. Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.
CAS Number
1383572-19-7
Product Name Alternative
XRP6258-d9; RPR-116258A-d9; taxoid XRP6258-d9
UNSPSC
12352005
Hazard Statement
H302+H312+H332, H315, H319
Target
Autophagy; Isotope-Labeled Compounds; Microtubule/Tubulin
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
99.4
Solubility
DMSO : 100 mg/mL (ultrasonic; warming)
Smiles
CC(O[C@]12[C@@]3([H])[C@@H]([C@]4(C(C)(C([C@H](C([C@@]3([C@H](C[C@@]1([H])OC2)OC)C)=O)OC)=C([C@H](C4)OC([C@H](O)[C@H](C5=CC=CC=C5)NC(OC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)=O)C)C)O)OC(C6=CC=CC=C6)=O)=O
Molecular Formula
C45H48D9NO14
Molecular Weight
844.99
Precautions
H302+H312+H332, H315, H319
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond) . 2017 Sep;12 (17) :2083-2095.|[3]Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Alternative Products